Tesamorelin

A stabilized growth-hormone-releasing hormone analog and the active ingredient of an FDA-approved therapeutic.

01Overview

Tesamorelin is a stabilized analog of GHRH. Unlike most compounds catalogued here, it is the active pharmaceutical ingredient of Egrifta, an FDA-approved medicine — so blanket “not evaluated by the FDA” language does not apply to the molecule itself.

It is studied for its effect on growth-hormone release and, distinctively, on visceral adipose tissue.

02Mechanism

• Binds pituitary GHRH receptors to stimulate GH secretion.
• The stabilizing modification extends half-life versus native GHRH.
• Drives reductions in visceral fat via downstream GH/IGF-1 signaling in studies.

03Research uses

• Growth-hormone-axis research
• Visceral-adiposity and lipid-metabolism models
• Body-composition studies

04Key findings

• Clinically shown to reduce visceral adipose tissue in its approved indication.
• Raises IGF-1; long-term studies monitor glucose metabolism.
• More potent and longer-acting than sermorelin in head-to-head handling.

05Handling & reconstitution

• Supplied lyophilized; requires careful reconstitution.
• Reconstitute with the specified diluent; swirl gently, never shake.
• Store lyophilized cold and protected from light; use reconstituted solution promptly.